Abivax ADR (NASDAQ:ABVX) traded at $6.43 at close of the session on Monday, March 10 and made a downward move of -18.71% on its previous day’s price.
Abivax ADR has a market cap of $407.47 million and is expected to release its quarterly earnings report in April.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 3.41M, with a low of 3.41M and a high of 3.41M. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 8.04M, or 74.72% up from figures reported last year.
On the other hand, looking at the outlook for the ABVX stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell.
Based on estimates by 1 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Abivax ADR (ABVX) stock as a Hold, while 1 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is -13.17% off its SMA20 and -6.25% from its 50-day simple moving average. The RSI (14) is pointing at 40.47 while the volatility over the past week is 11.31% and jumps to 7.35% over the past one month. The beta value is -0.26, while the average true range (ATR) is currently pointing at 0.57. The average price target for the stock over the next 12 months is $42.5, with the estimates having a low of $42 and a high of $43. These price ends are -553.19% and -568.74% off the current price level respectively, although investors could be excited at the prospect of a -560.96% if the ABVX share price touches on the median price of $42.5.
